APTO•benzinga•
Aptose Biosciences Announced Initiation Of The TUSCANY Study, Tuspetinib In Combination Therapy With Azacitidine And Venetoclax As A Frontline Triplet Combination Therapy For Patients Newly Diagnosed With Acute Myeloid Leukemia
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 20, 2024 by benzinga